Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$751 Mln
P/E Ratio
--
P/B Ratio
0.71
Industry P/E
--
Debt to Equity
0.06
ROE
-0.15 %
ROCE
-13.88 %
Div. Yield
0 %
Book Value
3.59
EPS
-0.55
CFO
$507.02 Mln
EBITDA
$255.31 Mln
Net Profit
$126.72 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| -19.97 | -28.29 | -15.95 | -50.21 | -35.70 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| -43.63 | -29.16 | -64.46 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 8.23 | 1,120.69 | 204 | 1.52 | |
| 5.35 | 246.73 | -- | -46.03 | |
| 3.50 | 100.90 | -- | -16.27 | |
| 35.19 | 2,703.49 | -- | -27.85 |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic... and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 Read more
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
Headquarters
Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Abcellera Biologics Inc (ABCL) stood at $ 1,361 Mln as on 31-Dec-24
The share price of Abcellera Biologics Inc (ABCL) is $2.35 (NASDAQ) as of 18-Mar-2025 14:35 EDT. Abcellera Biologics Inc (ABCL) has given a return of -35.7% in the last 3 years.
Abcellera Biologics Inc (ABCL) has a market capitalisation of $ 751 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Abcellera Biologics Inc (ABCL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Abcellera Biologics Inc (ABCL) and enter the required number of quantities and click on buy to purchase the shares of Abcellera Biologics Inc (ABCL).
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
The CEO & director of Dr. Carl L.G. Hansen Ph.D.. is Abcellera Biologics Inc (ABCL), and CFO & Sr. VP is Dr. Carl L.G. Hansen Ph.D..
There is no promoter pledging in Abcellera Biologics Inc (ABCL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
23
|
|
|
22
|
| Abcellera Biologics Inc (ABCL) | Ratios |
|---|---|
|
Return on equity(%)
|
-14.75
|
|
Operating margin(%)
|
-1044.45
|
|
Net Margin(%)
|
-564.83
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Abcellera Biologics Inc (ABCL) was $0 Mln.
$-0.20
(
